title: Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
authors.forename: Anton B
authors.initials: AB
authors.lastname: Alexandroff
authors.forename: Volha
authors.initials: V
authors.lastname: Shpadaruk
authors.forename: W Mark
authors.initials: WM
authors.lastname: Bamford
authors.forename: D Ben J
authors.initials: DB
authors.lastname: Kennedy
authors.forename: Robert
authors.initials: R
authors.lastname: Burd
authors.forename: Martin J S
authors.initials: MJ
authors.lastname: Dyer
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D012751:Sezary Syndrome / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab; C520522:zanolimumab